Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Novo Nordisk AS

www.novonordisk.com

Latest From Novo Nordisk AS

Biohaven Pays $105m For Turbo Boost In Migraine Drug Review Race

Biohaven has acquired a priority review voucher from GW Pharma to accelerate the US review of rimegepant, its oral CGRP receptor antagonist for migraine. The firm is competing with Allergan and Lilly in a race to get the next oral treatment approved.

Drug Review Neurology

Lundbeck Leads $50m Fund Raise For CRISPR Microbiome StartUp

A Danish company with a novel approach to gene editing for antibacterials has raised $50m in a series A round, using the cash injection to advance its ambition to be testing drug candidates in humans by 2021.

Financing StartUps and SMEs

Clinical Trial Data Highlight Korean Pharma’s R&D Shift Into Innovation

New clinical trial approval data show that early-stage studies of novel drug candidates by South Korean pharma and biotech firms sharply increased in 2018, underlining the industry’s ongoing shift towards innovation. Trials of oncology drugs continued to dominate, while clinical work in rare disorders such as hemophilia and Crohn’s disease has noticeably increased.

South Korea Clinical Trials

Keeping Track Of Non-Oncology Review and Approval News: Erectile Dysfunction, Parkinson's, Cholesterol

The latest non-oncology drug development news and highlights from our US FDA Performance Tracker.
Drug Review Regulation
See All

Company Information

Advertisement
Advertisement
UsernamePublicRestriction

Register